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Abstract Non-alcoholic fatty liver disease (NAFLD) is a
major complication linked with the metabolic syndrome
associated with dyslipidemia, inflammation, and oxidative
stress. Impact of type 2 diabetes with hyperlipidemia in
NAFLD has to be established, as well as the utility of
commonly prescribed anti-diabetic and lipid-lowering
agents in improving liver injury markers. Genetic type 2
diabetic Goto–Kakizaki rats were fed with a high-fat diet to
test hepatic effects of type 2 diabetes with hyperlipidemia
and the effect of atorvastatin and insulin, individually and
in combination, in systemic and hepatic inflammatory and
oxidative stress markers. High-fat diet aggravated fasting
glycemia, systemic and liver lipids, and inflammatory and
oxidative stress markers. Individual treatments improved
glycemic and lipid profiles, but failed to improve inflam-
matory markers, whereas insulin was able to reduce liver
oxidative stress parameters. Combination of insulin and
atorvastatin further improved glycemic and lipid profiles
and decreased circulating C-reactive protein levels and liver
inflammatory and oxidative stress markers. Insulin and
atorvastatin combination leads to better glycaemic and lipid
profiles and to better protection against liver inflammation
and oxidative stress, giving a superior level of liver
protection in type 2 diabetic with hyperlipidemia.
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Abbreviations
NAFLD Non-alcoholic fatty liver disease
NASH Non-alcoholic steatohepatitis
CRP C-reactive protein
TNF-α Tumour necrosis factor α
IL-6 Interleukin-6
Introduction
In the USA, 20% of the adults have diagnosed non-
alcoholic fatty liver disease (NAFLD) and 2–3% develops
non-alcoholic steatohepatitis (NASH; Cave et al. 2007).
NAFLD, which is currently understood as the liver
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expression of the metabolic syndrome, is considered when
triglycerides drops occupy more than 5% of the hepatocyte
(Maeda et al. 2005; Neushwander-Tetri 2005). Subjects
with NAFLD currently have more visceral fat, insulin
resistance, higher levels of C-reactive protein (CRP), free
fatty acids (FFA), triglycerides and oxidative stress
markers, and lower levels of HDL-cholesterol (Brownlee
2005; Bugianesi et al. 2005a, b; Hanley et al. 2005).
Insulin resistance was reported to be significantly
correlated with NAFLD; previous reports showed that
normal but not genetic type 2 diabetic Goto–Kakizaki rats
subjected to high-fat diet have increased insulin secretion
compensating for high-fat-diet-induced insulin resistance
(Ota et al. 2007; Shang et al. 2002). Insulin promotes free
fatty acids storage in adipocytes and inhibits lipolysis
(Bradbury 2006). Hyperlipidemia leads to accumulation of
free fatty acids and their metabolites in hepatocytes, which
is associated with activation of inflammatory pathways,
namely tumor necrosis factor-α (TNF-α), interleukin-6
(IL-6), and CRP, directly causing insulin resistance (Kaneto
et al. 2005; Paumelle et al. 2006; Sethi and Hotamisligil
1999). CRP, in addition to its atherosclerotic effects,
severely induces insulin resistance (Yki-Järvinen 2005;
Shoelson et al. 2007) and is negatively related with HDL-
cholesterol levels (Chrysohoou et al. 2006; Pfützner and
Forst 2006) and directly with the degree of liver fibrosis
(Yoneda et al. 2007)
In obese and type 2 diabetic patients with NASH,
adiponectin levels are inversely associated with hepatic
steatosis, inflammation, and fibrosis (Meier and Gressner
2004; Yamauchi et al. 2003; Zhou et al. 2005). Furthermore,
in normal, but not NASH patients, lipid infusion stimulates
adiponectin production (Makowski and Hotamisligil 2005).
Insulin has been widely used among type 2 diabetic
patients in order to balance β cell failure. Recent standards
in medical care suggest insulin therapy in early stages of
type 2 diabetes and combination with other therapies,
namely statins (Maseri 1995). However, the usefulness of
insulin therapy in complications associated with the
metabolic syndrome remains to be elucidated.
Atorvastatin is among the most clinically used statins
(HMG-CoA reductase inhibitors, a key enzyme of the
hepatic cholesterol biosynthesis pathway; Ludwig et al.
2005). Cholesterol produced in the liver incorporates
mostly in low-density lipoproteins (LDL), named LDL-
cholesterol, which directly correlates with atherosclerosis
(Bisgaier et al. 1997; Davidson 2005). It has been
suggested that statins have acute anti-inflammatory proper-
ties, promoting fatty acid oxidation; however, the effects of
chronic statin therapy is not entirely established (Planavila
et al. 2005). Recent papers have suggested that statin
therapy can also have beneficial effects in liver; however,
their full extent is not known due to the absence of clinical
studies in this field (Ekstedt et al. 2007; Georgescu and
Georgescu 2007).
In this study, we evaluated the hepatic effects of high-fat
diet in Goto–Kakizaki rats, a spontaneous animal model of
type 2 diabetes, and the effects of atorvastatin and insulin,
individually and in combination, in this animal model in a
young age. Our aim was to assess whether the simultaneous
use of atorvastatin and insulin has positive impacts, beyond
their individual effects, in liver inflammation and oxidative
stress.
Materials and methods
Reagents
All compounds were of the purest quality available and
were purchased from Sigma Chemical (St. Louis, MO,
USA) or Merck (Darmstadt, Germany).
Animals
Goto–Kakizaki rats, obtained from our local breeding
colony (Animal Research Center Laboratory, University
Hospital, Coimbra, Portugal), were kept under controlled
light (12 h day/night), temperature (22–24°C), and humid-
ity (50–60%) conditions and with free access to water and
to standard (Charles River) or to high-fat diet [special diet
0125 (modified A04 from Charles River) SAFE, France]
which is composed of 70% AO4 standard chow, 7.5%
cocoa butter, and 1.25% cholesterol.
Rats were divided into five experimental groups (n=12
per group): one group (SD) maintained with standard diet
until 6 months of age and four groups maintained with
high-fat diet between 2 and 6 months of age. The high-fat
groups were divided according to the treatment [no
treatment (AD); insulin (ADI); atorvastatin (ADA); ator-
vastatin and insulin (ADAI)]. The experimental protocol
was approved by the local Institutional Animal Care and
Use Committee.
Treatment administration
Insulin and atorvastatin were administered during the last
month (between 5 and 6 months of age). Insulin (Mixtard
30 Novolet, from Novo Nordisk A/S, Denmark) was
administered twice a day subcutaneously according to
glucose levels: glycemia between 150 and 199 mg/ml,
2 U of insulin; glycemia between 200 and 299 mg/dl,
4 U; glycemia higher than 300 mg/dl—6 U. Atorvastatin
(Pfizer, USA) was administered orally (10 mg kg−1 day−1),
diluted in water (equivalent to the maximum human dose,
40 mg/day).
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Sample collection and storage
At the end of the treatment (6 months), rats were placed in
metabolic boxes for 24 h and urine was collected. Urine
was centrifuged 2000×g, 10 min, 4°C and stored at −80°C.
In another day, blood samples were collected after an
overnight fasting by cardiac puncture from anesthetized
animals [ketamine chloride (75 mg/kg, im, Parke-Davis,
Ann Arbor, MI, USA) and chlorpromazine chloride
(2.65 mg/kg, im, Lab. Vitória, Portugal)]. For plasma and
serum parameters determination, blood was centrifuged
(2,500 rpm), 10 min, 4°C, aliquoted, and stored at −20°C.
Animals were killed by cervical dislocation and livers were
immediately collected and briefly washed in NaCl (0.9%).
Liver sections from ten animals per group were fixed in
10% buffered formalin and embedded in paraffin for
histological analysis. Remaining tissue was frozen in liquid
nitrogen and stored at −80°C.
Blood glucose and plasma insulin levels
Blood glucose levels, fasting and 2 h after glucose load
(1.8 g/kg), were determined through the glucose oxidase
method using a glucometer (Elite-Bayer, Portugal). Plasma
insulin was determined by an in-house competitive
enzyme-linked immunosorbent assay (ELISA) as previous-
ly described (Nunes et al. 2007; Seiça et al. 2004).
Immunoglobulin G-certified microtiter plates (96 wells,
Nunc, Roskilde, Denmark) were incubated overnight at
4°C, with guinea pig–rat insulin serum (Biotrend Chem-
ikalien, GmbH) using rat insulin as standard (Linco
Research Inc, USA). 3,3′, 5,5′-tetrametilbenzidine (TMB,
liquid substrate system; Sigma Chemicals) was used as
substrate for the insulin–peroxidase conjugate, and the
reaction product was assayed spectrophotometrically
(450 nm; Gen5, Biotek Instruments, USA) after a 30-min
incubation with TMB at room temperature (the reaction
was stopped with sulfuric acid).
Insulin resistance was measured through the homeostasis
model assessment (HOMA) index and the quantitative
insulin sensitivity index (QUICKI). HOMA was calculated
as [(If) × (Gf)]/22.5, where (If) is the fasting insulin level
(μU/ml) and (Gf) is the fasting glucose level (mmol/L;
Chen et al. 2005). QUICKI was calculated as 1/[log(G0) +
log(I0)], where G0 is fasting glucose (mg/dL) and I0 is
fasting insulin (μU/ml; Chen et al. 2005).
Circulating and liver lipids
Serum triglycerides and cholesterol (total and HDL) and
liver triglycerides and cholesterol levels were determined
using commercial kits (Olympus-Diagnóstica Portugal,
Produtos de Diagnóstico SA, Portugal). Atherogenicity
index (A.I.) was calculated as total cholesterol/HDL-
cholesterol. Plasma free fatty acid levels were determined
using the half-micro test, Roche Diagnostic, Germany.
For liver lipid content determination, liver sections
(1.25 g) were homogenized in 7.5 ml chloroform/methanol
(2:1, v/v) solution and vortexed during 15 min. Chloroform
(2.5 ml) and ultra pure water (2.5 ml) were added and
homogenates were centrifuged at 3,000 rpm, 8 min, 4°C.
The lower (chloroform) phase was collected in a clean tube.
In the first tube, 3.76 ml of chloroform was added. Samples
were vortexed and centrifuged at 3,000 rpm, 8 min, 4°C.
Chloroform phase was collected and added to chloroform
phase from first centrifugation. Samples were evaporated at
55°C under nitrogen atmosphere and suspended in 2 ml of
2-propanol for lipid measure.
Inflammatory markers
Serum C-reactive protein levels were measured using the C-
reactive protein ELISA kit, and circulating and hepatic
TNF-α and IL-6 levels were determined by the rat TNF
ELISA set and rat IL-6 ELISA set, respectively (BD
Biosciences Pharmingen, CA, USA). Serum levels of
adiponectin were quantified by the ELISA Phoenix adipo-
nectin kit assay (Phoenix, USA). Liver sections (200 mg)
were homogenized in 2 ml of cold 25 mM Tris–HCl buffer
containing 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X-100, 10 mM PMSF and protease inhibitors
cocktail, pH=7.4. Homogenates were centrifuged at
14,000 rpm, 20 min, 4°C. Supernatant was transferred to
a clean tube and centrifuged at 14,000 rpm, 15 min, 4°C.
Supernatant was collected, aliquoted, and stored at −80°C.
Oxidative stress markers
Plasma and liver carbonyl protein concentration was
determined using the protein carbonyl assay (Cayman
Chemical Company, USA). Liver was homogenized in cold
buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH=7.4)
and centrifuged at 10,000 rpm, 15 min, 4°C. Supernatants
were stored at −80°C.
Urine and liver free 8-isoprostane was determined using
the 8-isoprostane EIA assay (Cayman Chemical Company).
Liver was homogenized in 0.1 M cold phosphate-buffered
solution containing 1 mM EDTA and 10 μM indomethacin
and was stored at −80°C according to the manufacturer’s
instructions.
Histological analysis
The 4-μm-thick paraffinized liver sections were deparaffi-
nized with xylene and rehydrated through decreasing concen-
trations of ethanol for staining with hematoxylin–eosin.
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Statistics
Data are presented as mean±SEM. Statistical differences
between AD and SD groups were determined by Student’s t
test. One-way analysis of variance and Tukey multiple
comparison test were used to assess differences between
treatments. A value of P <0.05 was considered statistically
significant.
Results
Body weight and food consumption
High-fat diet significantly increased body weigh (P<
0.001). None of the treatments significantly altered this
parameter in comparison to AD group (Table 1). Food
consumption was similar in all experimental groups
(Table 1).
High-fat diet increases fasting glycemia and aggravates
lipid profile
Fasting glycemia was significantly higher in atherogenic
diet group than in standard diet group (P<0.001; Table 1).
Glycemia 2 h after intraperitoneal glucose administration
and insulin resistance indexes were not changed by
atherogenic diet (Table 1).
High-fat diet group increased total cholesterol (P<0.05)
and reduced HDL-cholesterol circulating levels (P<0.001)
when compared with SD group (Table 2). Furthermore,
higher A.I. (total/HDL-cholesterol; P<0.001), triglyceride
(P<0.01), and FFA (P<0.001) levels were observed in AD
group (Table 2).
Insulin and atorvastatin combination further improve
glycemic and lipid profiles
Fasting glycemia was significantly decreased by all treatments
(P<0.001). However, atorvastatin resulted in a less pro-
nounced effect than observed in ADI and ADAI (P<0.001;
Table 1). In relation to AD group insulin and atorvastatin
groups had shown no improvements in glycemia 2 h after
glucose administration; only the combination therapy
resulted in significant improvements when compared to AD
(P<0.001), ADI (P<0.05), and ADA (P<0.01) groups
(Table 1). When compared with AD group, atorvastatin
treatment significantly improved HOMA (P<0.05) and
QUICKI (P<0.01), but a more pronounced effect was
observed with insulin and combination treatment in both
HOMA (P<0.01) and QUICKI (P<0.001). In QUICKI,
combination treatment also showed a significant difference
when compared to atorvastatin group (P<0.05), thus further
improving insulin sensitivity (Table 1).
Treatments did not alter total cholesterol levels in
relation to AD group (Table 2); however, all of them
significantly improved HDL-cholesterol levels (P<0.01;
Table 2). Although HDL-cholesterol was improved in all
groups, only the group receiving both insulin and atorva-
statin showed a significant decrease in A.I. in comparison
to AD (P<0.05) and ADI groups (P<0.05; Table 2). When
comparing with high-fat diet group, the triglycerides
concentration did not change with the treatments, but all
of them significantly decreased fasting free fatty acid levels
(P<0.001; Table 2).
Liver weight
Liver weight, expressed as percentage of body weight, was
higher in high-fat diet group than in standard diet group
Table 1 Body (g) and liver (% of body weight) weight, food consumption (grams per rat per day), glycemia (mmol/L), fasting and 2 h after
intraperitoneal glucose administration (1.8 g/kg), and insulin resistance indexes
Parameter SD AD ADI ADA ADAI
Body weight (g) 345±8 387±17a*** 392±5 401±7 391±5
Diet (grams per rat per day) 23±0 19±2 19±1 20±1 18±1
%LiverW/bodyW 4.1±0.1 4.7±0.2
a* 3.6±0.1b*** 3.5±0.1b*** 3.4±0.1b***
Fasting glycemia (mmol/L) 5.2±0.1 7.8±0.2a*** 5.4±0.1b,d*** 6.6±0.1b*** 5.0±0.1b,d***
Glycemia at 2 h (mmol/L) 16.6±0.4 16.8±0.8 14.9±0.8 16.0±0.6 12.3±07b,c,d***,*,**
HOMA 11.2±1.3 14.7±2.5 5.3±1.0b** 7.3±0.8b* 4.8±1.2b**
QUICKI 0.29±0.06 0.27±0.04 0.31±0.08b*** 0.29±0.05b** 0.32±0.09b,d***,*
Data are presented as means±SEM
SD standard diet, AD atherogenic diet, ADI AD + insulin, ADA AD + atorvastatin, ADAI AD + atorvastatin plus insulin (n=12)
*P<0.05; **P<0.01; ***P<0.001
a Represents significant differences from SD group
b Represents a significant difference from the AD group
c Represents a significant difference from insulin group
d Represents significant differences from atorvastatin group
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(P<0.05). All treatments prevented liver hypertrophy
observed in AD group (P<0.001; Table 1).
Treatments fail to improve high-fat diet-induced lipid
accumulation in liver
Liver cholesterol (P<0.001) and triglycerides (P<0.001)
levels were significantly increased by high-fat diet. Treat-
ments were not able to improve these parameters (Fig. 1a,b).
High-fat diet aggravates systemic and hepatic inflammatory
status
High-fat diet did not result in significant adiponectin
alterations (Table 2), but significantly increased CRP
circulating levels in relation to standard diet-fed rats (P<
0.05; Fig. 2a). Circulating TNF-α and IL-6 levels were also
measured, but these values were below the detection limit
in all experimental groups (TNF-α<15.6 pg/ml; IL-6<
39 pg/ml), thus suggesting that is not an issue in this model.
Liver TNF-α and IL-6 concentrations were determined
as markers of liver inflammation. Atherogenic diet signif-
icantly increased both cytokines concentration in relation to
SD group (TNF-α: P<0.001; IL-6: P<0.001; Fig. 2b,c).
Combination treatment further improve inflammatory status
Insulin and combination treatment did not significantly alter
adiponectinemia (Table 2). Atorvastatin significantly decreased
circulating adiponectin levels as compared to AD (P<0.001)
ADI (P<0.001), and ADAI groups (P<0.001; Table 2).
Isolated insulin and atorvastatin had no significant
effects in circulating CRP and liver TNF-α and IL-6 levels.
Only therapy combination significantly improved each of
these inflammatory markers (P<0.05) when compared to
the AD group (Fig. 3a–c). There were no observed
significant differences between treatments.
High-fat diet increases systemic and hepatic oxidative stress
markers
Systemic and liver protein carbonyl and free 8-isoprostane
levels were determined as markers of oxidative stress. Our
data show that high-fat diet increased systemic protein
Table 2 Total and HDL-cholesterol (mg/dL), atherogenicity index (AI), triglycerides (mg/dL), plasma FFAs (mM), and adiponectin levels (μg/ml)
Parameter SD AD ADI ADA ADAI
Total cholesterol (mg/dL) 88.9±1.9 100.4±5.3a* 105.1±3.9 116.4±8.1 96.5±4.3d*
HDL-cholesterol (mg/dL) 61.4±1.3 48.8±0.9a*** 53.7±1.0b** 59.4±2.6b** 55.3±1.7b**
A.I. 1.45±0.01 2.02±1.01a*** 1.96±0.06 1.87±0.05 1.74±0.04b,d*
Triglycerides (mg/dL) 149.5±11.6 222.9±20a** 193.7±8.5 271.7±23 196.4±12.2
FFA (mM) 0.79±0.04 1.13±0.04a*** 0.79±0.06b*** 0.81±0.07b*** 0.69±0.06b***
Adiponectin (μg/ml) 4.6±0.3 5.2±0.3 6.1±0.6d*** 3.3±0.2b*** 4.9±0.4d***
Data are presented as means±SEM
SD standard diet, AD atherogenic diet, ADI AD + insulin, ADA AD + atorvastatin, ADAI AD + atorvastatin plus insulin (n=12)
*P<0.05; **P<0.01; ***P<0.001
a Represents significant differences from SD group
b Represents significant difference from the AD group
c Represents significant difference from insulin group
d Represents significant difference from atorvastatin group
Fig. 1 Liver cholesterol and tri-
glycerides levels (mg/g tissue) in
standard diet, high-fat diet, and
treatments groups. SD standard
diet, AD atherogenic diet, ADI
insulin, ADA atorvastatin, ADAI
atorvastatin plus insulin (n=8–9
per group). Data are presented as
means±SEM. +Represents
significant differences from
SD group (+++P<0.001)
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carbonyl levels (P<0.001) and did not significantly alter
free 8-isoprostane (Table 3). Liver carbonyl compounds
(P<0.001) and free 8-isoprostane (P<0.05) levels were
significantly higher in AD group when compared to SD
group (Fig. 4a,b).
Combination with atorvastatin enhances insulin effects
in decreasing liver oxidative stress
None of the treatments had a significant effect on
circulating protein carbonyl compounds and urine free
8-isoprostane levels despite an increase in free 8-isopros-
tane observed with individual atorvastatin treatment
(P<0.05; Table 3). Atorvastatin showed no effect in liver
levels of protein carbonyl and free 8-isoprostane (Fig. 5a,b).
Only insulin and its combination with atorvastatin resulted
in a significant decrease of both parameters in relation to
AD group (P. carbonyl: P<0.05; 8-isoprostane: P<0.05)
and atorvastatin group in liver protein carbonyl levels
(P<0.05; Fig. 5a,b). Furthermore, insulin and atorvastatin
combination induced a decrease of free 8-isoprostane in
relation to individual atorvastatin (P<0.05; Fig. 5b).
Fig. 3 Circulating CRP concen-
tration (μg/ml) (a) and liver
TNF-α (b) and IL-6 (c) con-
centrations (ng/mg protein) in
treatments and AD groups. AD
atherogenic diet, ADI insulin,
ADA atorvastatin, ADAI ator-
vastatin plus insulin (n=8–9 per
group). Data are presented as
means±SEM. *Represents a
significant difference from the
control group (*P<0.05)
Fig. 2 Circulating CRP concen-
tration (μg/ml) (a) and liver
TNF-α (b) and IL-6 (c) con-
centrations (ng/mg protein) in
standard and high-fat diet
groups. SD standard diet, AD
atherogenic diet (n=8–9 per
group). Data are presented as
means±SEM. +Represents sig-
nificant differences from SD
group (+P<0.05; +++P<0.001)
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High-fat diet causes portal inflammation
High-fat-fed rats showed an unspecific portal inflammation
(Fig. 6b, c) in a very significant range when compared to
SD group (Fig. 6a). Hepatic steatosis and fibrosis was not
observed at this age.
Combination of insulin and atorvastatin further improves
portal inflammation
Individual insulin and atorvastatin (Fig. 7b,c) partially
reverted inflammatory process observed in livers of high-
fat-fed rats (Fig. 7a). However, combination of atorvastatin
and insulin enhances the effects observed in each individual
treatment (Fig. 7d). In fact, combination treatment reduced
portal inflammation almost completely.
Discussion and conclusions
In this study, we show that high-fat diet aggravates
systemic and liver lipid profile and inflammatory and
oxidative markers in an animal model of type 2 diabetes.
Our data also show that combinatory use of insulin and
atorvastatin improves these parameters beyond the effects
of individual therapies, providing superior liver protection
in the context of type 2 diabetes and hyperlipidemia.
Atherogenic diet administration increases body and liver
weight and aggravates fasting glycemia, total and HDL-
cholesterol, atherogenicity index, triglycerides, free fatty
acids and liver lipids. Although circulating TNF-α and
IL-6 were not measurable and significant alterations in
adiponectin levels are not seen, liver TNF-α and IL-6 levels
and serum CRP levels are increased in this group,
suggesting an aggravated systemic and liver inflammatory
status. Accordingly, histological analysis shows that despite
high-fat diet not resulting in hepatic steatosis, an evident
portal inflammation was induced.
A recent study from Grimsrud et al. (2007) showed that
obesity and insulin resistance are associated with adipose
protein carbonylation. This study identified mechanisms of
protein carbonylation responsible for induction of insulin
resistance. Our results suggest that these mechanisms can
be involved in liver insulin resistance in conditions of
hyperlipidemia: High-fat diet increases liver concentration
of protein carbonyl and free 8-isoprotane.
Insulin is known to stimulate glucose and lipids uptake
and oxidation in target tissues as liver (Bugianesi et al.
2005b). Our data show that insulin treatment improves
fasting glycemia, insulin resistance indexes, free fatty acids,
and HDL-cholesterol. However, insulin treatment does not
improve CRP, adiponectin and liver lipids, and inflamma-
tory markers. Recent data showed that insulin is not able to
improve circulating adiponectin and CRP levels in diabetic
mice and in type 2 diabetes patients (Aas et al. 2006; Fujita
et al. 2005). Insulin can partially reduce portal inflamma-
tion, although it does not significantly decrease liver
inflammatory markers. Insulin is not able to improve
systemic oxidative stress markers, but a significant decrease
of the same markers in hepatic tissue is observed, showing
that it can be useful in reducing liver oxidative stress, a
major feature of NAFLD.
Atorvastatin is commonly prescribed as a non-HDL
cholesterol-decreasing agent. In agreement with previous
studies, atorvastatin significantly increases HDL cholesterol
and decreases free fatty acids (Bayés et al. 2005; Hernandez
Table 3 Plasma concentration of protein carbonyl (nmol/mL) and free 8-isoprostane in urine in 24 hours (ng/24 hours)
Parameter SD AD ADI ADA ADAI
Prot. carbonyl (nmol/mL) 23.5±1.1 38.1±3.0a** 35.8±3.7 31.0±2.2 33.8±2.7
8-Isoprostane (ng/24 h) 23.1±2.2 19.7±1.2 21.8±2.7 25.5±1.2b* 21.2±4.0
Data are presented as means±SEM
SD standard diet, AD atherogenic diet, ADI AD + insulin, ADA AD + atorvastatin, ADAI AD + atorvastatin plus insulin (n=8/9)
* P<0.05; **P<0.001
a Represents significant differences from SD group
b Represents a significant difference from the AD group
Fig. 4 Liver protein carbonyl (nmol/ mg protein) (a) and free 8-
isoprostane (ng/mg protein) (b) concentration in standard and high-fat
diet groups. SD standard diet, AD atherogenic diet (n=8–9 per group).
Data are presented as means±SEM. +Represents significant differ-
ences from SD group (+P<0.05; +++P<0.001)
Naunyn-Schmiedeberg’s Arch Pharmacol (2009) 379:241–251 247
et al. 2006; Shetty et al. 2004). Until now, many studies
have been done in order to test whether statins can improve
inflammatory status and glucose homeostasis besides the
lipid profile. Furthermore, the acute and chronic effects of
statins are not fully elucidated. Recent data showed that
statins have no effect on CRP levels or other inflammatory
markers (Bayés et al. 2005; Lam et al. 2006), or if so, it was
used in a concentration fivefold higher than the one used in
our study, exceeding the concentrations used in clinical
practice (Wong et al. 2006). In another recent study,
simvastatin had acute CRP-lowering properties, but this
effect decreased with time, returning circulating CRP levels
to baseline values (Hernandez et al. 2006). In our study, we
show that atorvastatin (10 mg kg−1 day−1 during 30 days) is
not able to significantly decrease CRP levels.
It was observed that atorvastatin has no effect on insulin
resistance in dyslipidemic patients (Bayés et al. 2005).
Satoh et al. (2005) showed that atorvastatin has no effect in
glucose tolerance in normal GK rats, and in this study, we
show that atorvastatin is also unable to improve glycemia
2 h after a glucose load in a context of hyperlipidemia in
the same animal model. However, in our study, atorvastatin
can improve insulin resistance indexes, although in a lesser
extent to that of insulin and combination treatment.
Our data also show that atorvastatin lower adiponectin
levels, which is an unexpected effect, since previous studies
showed that atorvastatin has no effect on circulating
adiponectin levels in diabetic patients (Bayés et al. 2005;
Shetty et al. 2004). However, a recent study from Forst et
al. (2007) reported that simvastatin treatment resulted in
Fig. 6 Liver tissue of standard
diet (a) and high-fat diet rats (b,
c). Arrows indicate portal in-
flammation, higher in AD
group. SD standard diet, AD
atherogenic diet. Hematoxylin–
eosin (×100)
Fig. 5 Liver protein carbonyl
(nmol/ mg protein) (a) and free
8-isoprostane (ng/ mg protein)
(b) in treatments and high-fat diet
groups. AD atherogenic diet, ADI
AD + insulin, ADA AD + ator-
vastatin, ADAI AD + atorvastatin
plus insulin (n=8–9 per group).
Data are presented as means±
SEM. *Represents a significant
difference from AD group (*P<
0.05). $Represents a significant
difference from atorvastatin
group ($P<0.05)
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adiponectin decrease in a non-diabetic population, and
Mäuser et al. (2007) showed that atorvastatin decreases
adiponectin synthesis in mature adipocytes, which may
explain our data. Our results reopen the question about the
interactions between atorvastatin and adiponectin.
Atorvastatin was not able to significantly reduce hepatic
lipids concentration and oxidative and inflammatory markers in
liver. However, histological analysis showed that atorvastatin
could partially reduce the degree of liver portal inflammation.
Although individual insulin and atorvastatin reduced
HOMA and QUICKI, insulin combination therapy further
improves these indexes. The combination of atorvastatin
and insulin also led to better glucose tolerance: Only
treatments in combination are able to improve glycemia 2 h
after a glucose load. As mentioned, atorvastatin decreases
circulating adiponectin levels when administered isolated,
but this effect is no longer observed when administered in
combination with insulin. Only treatments in combination
are able to reduce atherogenicity index, CRP circulating
levels, and liver TNF-α and IL-6 levels. Similar results are
obtained with histological analysis: Unlike individual
therapies, therapeutic combination results in a marked
reduction of inflammation in comparison to the high-fat
diet group.
Our data show that whole body oxidative stress is not
altered by the treatment combination. However, liver
protein carbonyl and free 8-isoprostane levels are signifi-
cantly diminished by insulin and combination treatment,
suggesting that insulin has a marked role in decreasing liver
oxidative stress and that atorvastatin can enhance it.
Current treatment of non-alcoholic hepatic steatosis
underlies weight loss (Comar and Sterling 2006; Federico
et al. 2006; Forst et al. 2007; Mäuser et al. 2007). Primary
therapies act over lipids and glucose homeostasis in order to
reduce insulin resistance. Available therapeutic options
include antioxidants, insulin sensitizers, hepatoprotectants,
and lipid-lowering drugs (Federico et al. 2006; Mäuser et
al. 2007). However, specific treatments are not established
due to the absence of randomized and controlled clinical
trials (Federico et al. 2006).
Fig. 7 Treatments groups in
comparison to high-fat diet
group. Arrows indicate portal
inflammation, lower in treat-
ments groups, namely ADAI
group. a AD atherogenic diet; b
ADI AD + insulin; c ADA AD +
atorvastatin; d ADAI AD +
atorvastatin plus insulin. Hema-
toxylin–eosin (×100)
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Recent standards in medical care suggest insulin therapy
in early stages of type 2 diabetes due to its effects in
lowering insulin resistance (Zhou et al. 2005). However,
insulin effectiveness in hepatic injuries is not elucidated.
This study suggests that insulin can have beneficial effects
in liver, namely in oxidative stress improvements. The
usefulness and safety of statins in the liver was recently
demonstrated in NAFLD patients through improvements in
progression to liver fibrosis, hepatic aminotransferases, and
liver lipid levels (Ekstedt et al. 2007; Georgescu and
Georgescu 2007; Gómez-Domínguez et al. 2006). In a
randomized study enrolling NAFLD patients, Athyros et al.
(2006) observed that atorvastatin produced better results
than fenofibrate in improving NAFLD and in ameliorating
circulating CRP and lipid levels. Our data show that
atorvastatin and insulin, by itself, have no major effects in
hepatic injury associated with type 2 diabetes with
hyperlipidemia. However, therapy combination produces,
in this animal model, improvements in liver inflammatory
and oxidative stress parameters beyond their individual
components. These results offer important mechanistic data
which reinforce the usefulness of this combination therapy
in improving metabolic profile and protecting liver in type
2 diabetes with hyperlipidemia.
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